[HTML][HTML] PSMA theranostics: Review of the current status of PSMA-targeted imaging and radioligand therapy
W Jones, K Griffiths, PC Barata, CJ Paller - Cancers, 2020 - mdpi.com
Prostate-specific membrane antigen (PSMA) has been the subject of extensive investigation
in the past two decades as a promising molecular target for prostate cancer (PCa). Its …
in the past two decades as a promising molecular target for prostate cancer (PCa). Its …
[HTML][HTML] The salivary glands as a dose limiting organ of PSMA-targeted radionuclide therapy: a review of the lessons learnt so far
N Heynickx, K Herrmann, K Vermeulen… - Nuclear medicine and …, 2021 - Elsevier
At present, prostate cancer remains the second most occurring cancer in men, in Europe.
Treatment efficacy for therapy of advanced metastatic disease, and metastatic castration …
Treatment efficacy for therapy of advanced metastatic disease, and metastatic castration …
[HTML][HTML] The 68Ga/177Lu-theragnostic concept in PSMA-targeting of metastatic castration–resistant prostate cancer: impact of post-therapeutic whole-body …
J Maffey-Steffan, L Scarpa, A Svirydenka… - European journal of …, 2020 - Springer
Introduction A new therapeutic option for metastatic castration–resistant prostate cancer
(mCRPC) of heavily pre-treated patients lies in 177 Lu-PSMA-617 radioligand therapy …
(mCRPC) of heavily pre-treated patients lies in 177 Lu-PSMA-617 radioligand therapy …
[HTML][HTML] Renal Safety of [177Lu]Lu-PSMA-617 Radioligand Therapy in Patients with Compromised Baseline Kidney Function
F Rosar, N Kochems, M Bartholomä, S Maus, T Stemler… - Cancers, 2021 - mdpi.com
Simple Summary Radioligand therapy (RLT) targeting prostate-specific membrane antigen
(PSMA) is an effective antitumor-treatment in metastatic castration-resistant prostate …
(PSMA) is an effective antitumor-treatment in metastatic castration-resistant prostate …
[HTML][HTML] Optimizing PSMA radioligand therapy for patients with metastatic castration-resistant prostate cancer. A systematic review and meta-analysis
FE von Eyben, G Bauman, R von Eyben… - International Journal of …, 2020 - mdpi.com
The aim of the review was to evaluate patient and treatment characteristics for patients with
metastatic castration-resistant prostate cancer (mCRPC) treated with PSMA radioligand …
metastatic castration-resistant prostate cancer (mCRPC) treated with PSMA radioligand …
PSMA-based theranostics: a step-by-step practical approach to diagnosis and therapy for mCRPC patients
H Ahmadzadehfar, K Rahbar, M Essler… - Seminars in Nuclear …, 2020 - Elsevier
To date, several papers have been published about prostate-specific membrane antigen
(PSMA)-based radioligand diagnostic and therapeutic approaches. This paper mainly …
(PSMA)-based radioligand diagnostic and therapeutic approaches. This paper mainly …
Renal cell carcinoma: the oncologist asks, can PSMA PET/CT answer?
C Pozzessere, M Bassanelli, A Ceribelli, S Rasul… - Current urology …, 2019 - Springer
Abstract Purpose of Review To critically review the potential clinical applications of prostate-
specific membrane antigen (PSMA) radioactive ligands in renal cell carcinoma (RCC) …
specific membrane antigen (PSMA) radioactive ligands in renal cell carcinoma (RCC) …
[HTML][HTML] Prostate-specific membrane antigen (PSMA) theranostics for treatment of oligometastatic prostate cancer
Theranostics, a combination of therapy and diagnostics, is a field of personalized medicine
involving the use of the same or similar radiopharmaceutical agents for the diagnosis and …
involving the use of the same or similar radiopharmaceutical agents for the diagnosis and …
[HTML][HTML] Towards Routine Clinical Use of Dosimetry in [177Lu]Lu-PSMA Prostate Cancer Radionuclide Therapy: Current Efforts and Future Perspectives
R Alsadi, M Djekidel, O Bouhali, JO Doherty - Frontiers in Physics, 2022 - frontiersin.org
In light of widely expanding personalized medicine applications and their impact on clinical
outcomes, it is naturally befitting to explore all the dimensional aspects of personalized …
outcomes, it is naturally befitting to explore all the dimensional aspects of personalized …
64Cu-labeled melanin nanoparticles for PET/CT and radionuclide therapy of tumor
H Zhou, Q Zhang, Y Cheng, L Xiang, G Shen… - … , Biology and Medicine, 2020 - Elsevier
Melanin is a group of natural pigments found in living organism. It can be used for positron
emission tomography (PET) imaging due to its inherent chelating ability to radioactive cupric …
emission tomography (PET) imaging due to its inherent chelating ability to radioactive cupric …